Armata Pharmaceuticals gets FDA Breakthrough for AP-SA02
U.S. FDA granted Breakthrough Therapy Designation for AP-SA02 in patients with complicated Staphylococcus aureus bacteremia, citing Phase 2 clinical data.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.